Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Julius

Showing results (31-40 of 115) with videos related to

Pageof 12
Sort By:
Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten|January 1, 1972
[Effect of propranolol and chlorophenoxybutyric acid (CPJB) on the dynamics of free fatty acids and blood sugar]H Haller, U Julius, W Leonhardt, et al.
Computer Methods and Programs in Biomedicine|July 1, 1990
Computer program for iterative evaluation of fractional turnover rates by exponential regression: application to the turnover of VLDL-triglycerides in bloodW Leonhardt, C Lüthke, F Leonhardt, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|December 1, 1994
Recovery of cholesterol and triacylglycerol in very-fast ultracentrifugation of human lipoproteins in a large range of concentrationsW Leonhardt, J Pietzsch, U Julius, et al.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete|June 15, 1977
[Significance of fatty tissue hypertrophy for the metabolic risk]W Leonhardt, M Hanefeld, U Julius, et al.
Atherosclerosis. Supplements|May 5, 2015
Hypertriglyceridemia in an outpatient department--Significance as an atherosclerotic risk factorM Scholz, S Tselmin, S Fischer, et al.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete|September 15, 1987
[Metabolism kinetic characterization of hypertriglyceridemias in drug therapy variations]J Schulze, U Julius, W Leonhardt, et al.
Atherosclerosis. Supplements|May 5, 2015
Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatmentS Schampera, S Fischer, N Weiss, et al.
Human Heredity|October 6, 2001
Estimation of the heritability of latent variables which are included in a structural model for metabolic syndromeR Koch, U Julius, W Jaross, et al.
Atherosclerosis. Supplements|May 5, 2015
Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital DresdenJ Dittrich-Riediger, U Schatz, B Hohenstein, et al.
Atherosclerosis. Supplements|February 5, 2010
Immunoadsorption for systemic lupus erythematosusG H Stummvoll, U Julius, K Derfler, et al.
Pageof 12

Showing results (31-40 of 115) with videos related to

Sort By:
Pageof 12
Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten|January 1, 1972
[Effect of propranolol and chlorophenoxybutyric acid (CPJB) on the dynamics of free fatty acids and blood sugar]H Haller, U Julius, W Leonhardt, et al.
Computer Methods and Programs in Biomedicine|July 1, 1990
Computer program for iterative evaluation of fractional turnover rates by exponential regression: application to the turnover of VLDL-triglycerides in bloodW Leonhardt, C Lüthke, F Leonhardt, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|December 1, 1994
Recovery of cholesterol and triacylglycerol in very-fast ultracentrifugation of human lipoproteins in a large range of concentrationsW Leonhardt, J Pietzsch, U Julius, et al.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete|June 15, 1977
[Significance of fatty tissue hypertrophy for the metabolic risk]W Leonhardt, M Hanefeld, U Julius, et al.
Atherosclerosis. Supplements|May 5, 2015
Hypertriglyceridemia in an outpatient department--Significance as an atherosclerotic risk factorM Scholz, S Tselmin, S Fischer, et al.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete|September 15, 1987
[Metabolism kinetic characterization of hypertriglyceridemias in drug therapy variations]J Schulze, U Julius, W Leonhardt, et al.
Atherosclerosis. Supplements|May 5, 2015
Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatmentS Schampera, S Fischer, N Weiss, et al.
Human Heredity|October 6, 2001
Estimation of the heritability of latent variables which are included in a structural model for metabolic syndromeR Koch, U Julius, W Jaross, et al.
Atherosclerosis. Supplements|May 5, 2015
Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital DresdenJ Dittrich-Riediger, U Schatz, B Hohenstein, et al.
Atherosclerosis. Supplements|February 5, 2010
Immunoadsorption for systemic lupus erythematosusG H Stummvoll, U Julius, K Derfler, et al.
Pageof 12